Trials / Active Not Recruiting
Active Not RecruitingNCT05826600
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
A Phase I/Ib Dose Escalation and Cohort Expansion Study of OMX-0407 a Salt-inducible Kinase Inhibitor in Patients With Previously Treated Unresectable Solid Tumours
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 188 (estimated)
- Sponsor
- iOmx Therapeutics AG · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the dose escalation phase of the study is to determine the safety of different doses of OMX-0407. The dose expansion (phase Ib) part of the study will evaluate efficacy, safety and tolerability at a dose determined in the dose escalation,
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OMX-0407 | Dose escalation, Dose expansion |
Timeline
- Start date
- 2023-03-30
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2023-04-24
- Last updated
- 2026-01-06
Locations
24 sites across 3 countries: Belgium, France, Spain
Source: ClinicalTrials.gov record NCT05826600. Inclusion in this directory is not an endorsement.